Binimetinib is an inhibitor that focuses on the MEK enzyme. It’s made just for people with melanoma who have the BRAF V600E/K mutation. The drug works by stopping the MEK signaling pathway, which is linked to how tumor cells grow.
It’s available as 15 mg tablets with a film coating. The usual amount for treating melanoma with the BRAF V600E/K mutation, when used with encorafenib, is 45 mg, taken twice daily. Each pack has 84 tablets, which should last a month if you take it as recommended.
Reviews
There are no reviews yet.